MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on October 6, 2004; DOI: 10.1124/mol.104.003863


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.104.003863v1
67/1/241    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barbier, o.
Right arrow Articles by Staels, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barbier, o.
Right arrow Articles by Staels, B.


Received for publication June 14, 2004.
Revised September 28, 2004.
Accepted for publication September 28, 2004.

Hepatic expression of the UGT1A9 gene is governed by HNF4{alpha}

olivier Barbier 1*, Hugo Girard 2, Yusuke Inoue 3, Helene Duez 4, Lyne Villeneuve 2, Akihide Kamiya 3, Jean-Charles Fruchart 4, Chantal Guillemette 2, Franck J Gonzalez 3, Bart Staels 4

1 Laval University 2 CHUL Research Center and Faculty of Pharmacy, Laval University, Quebec, Canada 3 Center for Cancer Research, NCI, NIH, Bethesda, USA 4 Institut Pasteur de Lille, France

* Address correspondence to: E-mail: olivier.barbier{at}pha.ulaval.ca

Abstract

UDP-glucuronosyltransferase (UGT) enzymes catalyze the glucuronidation reaction which is a major pathway in the catabolism and elimination of numerous endo- and xenobiotics. Among the UGT enzyme family members, the UGT1A7, UGT1A8, UGT1A9 and UGT1A10 isoforms are issued from a single gene through differential splicing. However, these enzymes display distinct tissue-specific expression patterns. Indeed, UGT1A7, UGT1A8 and UGT1A10 are exclusively expressed in extrahepatic tissues, whereas UGT1A9 transcripts are found at high concentrations in liver. In the present study, we report that the liver-enriched hepatocyte nuclear factor 4 (HNF4){alpha} controls the hepatic expression of the UGT1A9 enzyme. Liver-specific disruption of the HNF4{alpha} gene in mice drastically decreases liver UGT1A9 mRNA levels. Furthermore, a HNF4{alpha} response element (HNF4{alpha} RE) was identified in the promoter of human UGT1A9 at position -372 to -360 bp by transient transfection, electrophoretic mobility shift assays and chromatin immunoprecipitation experiments. Interestingly, this response element is absent in the proximal UGT1A7, UGT1A8 and UGT1A10 gene promoters. In conclusion, the present study identifies HNF4{alpha} as a major factor for the control of UGT1A9 hepatic expression and suggests that the absence of UGT1A7, UGT1A8 and UGT1A10 expression in the liver is due, at least in part, to few base pair changes in their promoter sequences in the region corresponding to the HNF4{alpha} RE of the UGT1A9 gene.


Key words: DNA binding sites, Promoter analysis, Receptor binding studies, Regulation of gene expression, Phase II enzymes, Regulation - transcriptional, UDP-glucuronyltransferases





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics